Document Detail

Clopidogrel in acute coronary syndrome: implications of recent study findings.
MedLine Citation:
PMID:  20828343     Owner:  NLM     Status:  MEDLINE    
The platelet ADP receptor antagonist clopidogrel is recommended for the treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention. Patients who received a coronary stent in particular should be protected by sufficient antiplatelet therapy to prevent stent thrombosis. Clopidogrel is a prodrug and has to undergo extensive metabolization before the active metabolite can irreversibly bind to platelets. This makes clopidogrel treatment susceptible to genetic and drug interactions. Recent study findings suggest that initial treatment with a higher dose of clopidogrel may be superior to the currently approved dose. It is not clear whether this approach will be sufficient to entirely overcome clopidogrel hyporesponsiveness, which worsens outcomes in up to one-third of patients. Newer antiplatelet agents are emerging but clopidogrel remains the best established treatment option, with more than 120,000 patients treated in randomized trials and 12 years of clinical postmarketing experience.
Daniel Duerschmied; Christoph Bode; Martin Moser
Related Documents :
15858933 - Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombos...
8836633 - Thrombolytic action of ticlopidine: possible mechanisms.
18041653 - Reactive oxygen species and human platelet gp iib/iiia receptor activation.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  8     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-10     Completed Date:  2010-12-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1215-29     Citation Subset:  IM    
University Hospital of Freiburg, Department of Cardiology and Angiology, Hugstetter Str. 55, 79106 Freiburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / drug therapy*
Angioplasty, Balloon, Coronary
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Purinergic P2Y Receptor Antagonists / administration & dosage,  adverse effects,  therapeutic use
Ticlopidine / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Purinergic P2Y Receptor Antagonists; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of life quality of pregnant adolescents with that of pregnant adults in Turkey.
Next Document:  Heart failure in 2010.